Skip to main content
Medical information Clinical review pending

Infection Testing

Human Immuno Virus Rapid Screening Test

A rapid screening test to detect antibodies for the Human Immunodeficiency Virus (HIV). Early detection is key for managing HIV/AIDS. Suitable for individuals at risk or showing symptoms.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (finger prick or venous draw). Confirm with the laboratory before booking.
Results
Results are typically available within a day. Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test. Confirm with the laboratory before booking.
Test priceKSh 514

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Human Immuno Virus Rapid Screening Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with potential exposure to HIV.
  • ✓People experiencing symptoms suggestive of HIV infection.
  • ✓Screening for pregnant women.
  • ✓Routine screening for individuals at higher risk.
  • ✓Confirmation of previous positive screening results.
02

In plain language

What this test helps you understand

This test is used for the initial screening of HIV infection by detecting antibodies produced by the body in response to the virus. Early detection allows for prompt medical care and management, improving patient outcomes and reducing transmission.
The Human Immuno Virus Rapid Screening Test is an essential diagnostic tool designed to detect the presence of the Human Immunodeficiency Virus (HIV) in individuals. This test is vital for early diagnosis, allowing for timely intervention and management of HIV/AIDS. With the rising prevalence of HIV in Kenya, this test plays a crucial role in public health by facilitating early detection and treatment.

This rapid screening test utilizes immunochromatography to detect antibodies to HIV in the serum. A positive result indicates the presence of HIV antibodies, suggesting an infection. It is important to note that a positive result should be followed by confirmatory testing.

Taking the Human Immuno Virus Rapid Screening Test offers numerous benefits, including early detection which can lead to timely treatment and management, helping reduce the risk of transmission to others, providing peace of mind, and allowing for informed health choices. Access to support services and counseling is also available for those who test positive.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test. Confirm with the laboratory before booking.
SampleBlood sample (finger prick or venous draw). Confirm with the laboratory before booking.
MethodologyImmunochromatographic assay (rapid test).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This is a screening test, not a diagnostic test. A positive result requires confirmation with further testing. Results may be negative in the early stages of infection (window period) before antibodies develop. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

This test detects antibodies your body produces in response to the Human Immunodeficiency Virus (HIV).
No, a positive result on this rapid screening test indicates the need for further confirmatory testing by a healthcare provider.
There is a 'window period' after exposure during which the test might be negative even if infected. Discuss this with your doctor.
Yes, all testing and results are handled with strict confidentiality according to medical ethics and regulations.
If you test positive, it is essential to consult with a healthcare provider immediately for confirmatory testing, counseling, and guidance on next steps.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp